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To the Editor:  57 
Immunodeficiency associated with mutations in the DNA cross-link repair 1C gene 58 
(DCLRE1C) can have variable clinical presentations including severe combined 59 
immunodeficiency (SCID), Omenn syndrome, atypical SCID or common variable 60 
immunodeficiency (CVID) (1)(2)(3). DCLRE1C encodes the protein Artemis, a nuclease with 61 
intrinsic 5′-3′ exonuclease activity on single-stranded DNA that is involved in non-62 
homologous end joining (NHEJ). Artemis is essential for V(D)J recombination of the 63 
immunoglobulin and T-cell receptor genes that occur during B- and T-cell development. 64 
Biallelic null mutations in DCLRE1C, completely ablating the function of Artemis, typically 65 
leads to T-, B-, radiosensitive SCID presenting in infancy, while biallelic hypomorphic 66 
mutations can cause a more variable clinical presentation that may present later during 67 
childhood or even in adults (1). We evaluated a five-year-old boy presenting with 68 
cytomegalovirus (CMV) pneumonia and long-term viral gastroenteritis. The patient was the 69 
son of consangious parents and first presented at 3 months post partum with upper 70 
respiratory tract infection and intermittent diarrhea, where the symptoms recurred in bouts 71 
during the following 5 years. He was evaluated for celiac disease, inflammatory bowel 72 
disease and food allergies without a conclusive diagnosis. The boy had normal psychomotor 73 
development and there was no failure to thrive, despite the recurrent symptoms. 74 
 75 
At the time of our evaluation the patient had developed a febrile illness with cough and 76 
worsened diarrhoea. Chest CT showed bilateral ground glass opacities and PCR detected 43 77 
000 copies/mL of CMV in bronchoalveolar lavage, with no other significant pathogens being 78 
identified. Simultaneous PCR of stool samples detected norovirus, enterovirus, adenovirus 79 
and astrovirus. CMV serology showed evidence of previous infection and the CMV 80 
pneumonitis was interpreted as a reactivation.  81 
 82 
Peripheral T-cell numbers were diminished and the proportion of double negative T-cells 83 
(CD3+CD4-CD8-) was elevated with at 20% of the peripheral T-cell population (Table 1). T-84 
cell responses to mitogens and recall responses to selected microbial antigens as evaluated 85 
by our clinical FASCIA method were impaired in the CD4+ T-cell subsets with the exception 86 
of responses to staphylococcal enterotoxin A which were normal (Table 1)(4). The peripheral 87 
B-cell population was reduced and showed a decreased level of naïve B-cells (IgD+ CD27-) 88 
and an increased proportion of switched memory B-cells (IgD-, CD27+) (Table 1). Serum 89 
concentrations of IgG and IgM were normal including IgG subclasses, while IgA was not 90 
detectable in serum (Table 1). Specific antibodies to several vaccine antigens (tetanus, 91 
diphtheria and pneumococcus) were also within the normal range (Table 1).  92 
 93 
The intriguing clinical picture and immunologic findings prompted us to perform whole-exome 94 
sequencing (WES). We identified a novel homozygous missense mutation in DCLRE1C. The 95 
mutation (c.272G>T, p.G91V) localized to the β-lactamase domain of Artemis, which is 96 
essential for its enzymatic activity (5). The mutation was predicted to be deleterious by 97 
several variant evaluation metrics (CADD score 34, Sift 0.9122) and the affected residue is 98 
conserved in several vertebrate species (phyloP100way 0.8579). The variant has previously 99 
not been described in the literature or in the ExAc and 1000 genomes databases. 100 
Confirmatory sanger sequencing revealed that the patient’s parents were both heterozygous 101 
carriers. In order to evaluate the effect of the mutation on V(D)J recombination, the patients 102 
TCR repertoire was analysed by spectratyping of 24 Vβ, 12 Vδ and 9 VƔ families (Figure 1). 103 
Compared to a healthy control analysed simultaneously the patients Vβ repertoire was 104 
aberrant with a non-Gaussian distribution across the majority of Vβ families and a disturbed 105 
appearance of the δ and Ɣ families. These findings indicate that the patients mutations in 106 
DCLRE1C gives rise to an Artemis protein that is unable to fully assist in V(D)J 107 
recombination and thus leads to an impaired TCR diversity, resulting clinically in atypical 108 
SCID. Assessing the impact of novel mutations in DCLREC1C on radio-sensitivity is clinically 109 
important, as increased radio sensitivity will affect a patients response to alkylating 110 
chemotherapy which is often used in the conditioning regiment of allogeneic hematopoietic 111 
stem cell transplantation (HCT)(6). We therefore cultured fibroblasts obtained by skin biopsy 112 
from the patient and exposed them to varying amounts of ionizing radiation. The patient’s 113 
fibroblasts showed a marked increase in radio-sensitivity compared to fibroblasts from a 114 
healthy donor (Table 1), indicating compromised DNA repair.  115 
 116 
The patients CMV pneumonia responded to treatment with ganciclovir. His gastroenteritis 117 
also improved during the following weeks with lessened stool frequency and volume.  A 118 
decision was made to perform HCT based on the clinical picture with progressive 119 
immunodeficiency and inability to control latent CMV in conjunction with immunologic 120 
findings indicating atypical radiosensitive SCID. The patient was conditioned with reduced 121 
dose fludarabin (150 mg/m2) and treosulfan (21g /m2), combined with antithymocyteglobulin 122 
(5 mg/kg).  Due to lack of HLA-matched donors, an in vitro TCR alpha/beta positive T-cell 123 
depleted peripheral blood stem cell graft from the patient's haploidentical father was used. 124 
The patient had an uneventful post-HCT course and is now in good clinical condition beyond 125 
the 2-year follow-up.  126 
 127 
In conclusion, we present a novel c.272G>T variant in DCLREC1C, associated with a 128 
radiosensitive atypical SCID with clinical signs of progressive T-cell deficiency. The patient 129 
had a restricted oligoclonal TCR repertoire associated with susceptibility to several viral 130 
infections. Surprisingly however the patient, despite a somewhat abnormal peripheral B-cell 131 
phenotype, had normal IgG levels including antibodies to vaccine antigens, indicating 132 
functional B-cell immunity. Additionally, the patient has no history infections with 133 
encapsulated bacteria, which further supports the presence of functional B-cell immunity. 134 
Taken together our findings associates the c.272G>T variant with atypical radiosensitive 135 
SCID. 136 
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Table 1 178 
   Patient  Normal range 179 
   
Peripheral cell numbers   
CD3+ T-cells 360 cells/µl 700-4200 cells/µl 
CD3+ CD4+ T-cells 80 cells/µl 300-2000 cells/µl 
CD3+ CD8+ T-cells 150 cells/µl 300-1800 cells/µl 
CD3+ CD8- CD4- DN-T-cells 20% 2-9% 
CD56+ NK-cells 1520 cells/µl 90-900 cells/µl 
CD19+ B-cells 90 cells/µl 200-1600 cells/µl 
IgD+ CD27- (Naïve) 16% 76-85% 
IgD- CD27+ (Switched) 34% 5-12% 
   
T-cell activation by FASCIA   
SEA CD4+ T-cells       1951 blasts/ µl 553-7743 blasts/ µl 
PWM CD4+ T-cells 85      blasts/ µl 233-2189 blasts/ µl 
ConA CD4+ T-cells 99      blasts/ µl 620-3800 blasts/ µl 
PPD Tb CD4+ T-cells 0        blasts/ µl 11-2022    blasts/ µl 
Pnc CD4+ T-cells 0        blasts/ µl   0-269         blasts/ µl 
   
Serum immunoglobulins   
IgG 13.6 g/L 6.1-14.5 g/L 
IgA <0.08 g/L 0.50-2.70 g/L 
IgM 0.52 g/L 0.27-1.50 g/L 
   
Serum antibodies   
Tetanus (IgG) 3.2 IE/mL 0.09-13 IE/mL 
Diphtheria (IgG) 0.065 IE/mL >0.01 IE/mL 
Pneumococcus (IgG) 53 mg/L 9.2-230 mg/L 
   
Radio-sensitivity of primary 
fibroblasts               
 HC 
No radiation 100% 100% 
1 G 43% 94% 
3G 14% 19% 
6G 4% 5% 
   
 180 
Table 1 181 
Laboratory investigations of the patient’s peripheral B-cell sub-populations are expressed as 182 
% of CD19+ peripheral B-cells. FASCIA responses are expressed as number of CD4+ T-cell 183 
blasts/ µl. IgG antibodies towards Pneumococcus was assessed as a total response against 184 
a combination of serotypes (1-5, 6B, F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 185 
19A, 20, 22F, 23F and 33F). Survival of skin biopsy derived, cultured primary fibroblast 186 
exposed to ionizing radiation, numbers are expressed as % surviving cells. Normal values 187 
are derived from analysis of fibroblast from a healthy control (HC) analysed at the same time. 188 
SEA, Staphylococcal enterotoxin A, PWM, Pokeweed mitogen, ConA, Concanavalin A, PPD 189 
Tb, Purified protein derivative Tuberculin, Pnc, Pneumococcus. G, Gray. 190 
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 Figure 1. TCR Vβ, Vδ and Vγ CDR3 spectratyping of the patient and a healthy 212 
control. The figures present a selection of representative Vβ, Vδ and Vγ families. 213 
TCR, T-cell receptor. 214 
 215 
